PGAM
DFTX

Princeton Global Asset Management’s Definium Therapeutics DFTX Stock Holding History

Princeton Global Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100
Closed -$570 – 647
2023
Q4 		$366 Hold
100
– – ﹤0.01% 628
2023
Q3 		$313 Hold
100
– – ﹤0.01% 572
2023
Q2 		$357 Hold
100
– – ﹤0.01% 565
2023
Q1 		$317 Hold
100
– – ﹤0.01% 571
2022
Q4 		$0 Hold
100
– – ﹤0.01% 569
2022
Q3 		$0 Hold
100
– – ﹤0.01% 553
2022
Q2 		$1K Buy
+100
New +$1.26K ﹤0.01% 535

Other funds holding DFTX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Princeton Global Asset Management's DFTX Position: Q1 2024 in Review

Princeton Global Asset Management sold out of Definium Therapeutics (DFTX) in Q1 2024, closing a stake of 100 shares — an estimated $570 sold.

Princeton Global Asset Management first reported a position in DFTX in Q2 2022 and held it in 7 quarters. The position peaked at $1K in Q2 2022. 135 funds tracked by Wall St. Rank hold DFTX as of Q1 2024.

  • Princeton Global Asset Management reported no remaining Definium Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Princeton Global Asset Management sold 100 Definium Therapeutics shares in Q1 2024, an estimated $570.
  • Princeton Global Asset Management first reported a position in Definium Therapeutics in Q2 2022 and held it in 7 quarters.
  • Princeton Global Asset Management's Definium Therapeutics position peaked at $1K in Q2 2022.
  • 135 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2024.

Based on Princeton Global Asset Management's 13F filing for Q1 2024, filed 29 Apr 2024.